These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 10578695)

  • 1. [Mineralocorticoid-like hypertension. "Apparent mineralocorticoid excess". A hereditary type of hypertension?].
    Christensen TH; Kaae HH; Ibsen H
    Ugeskr Laeger; 1999 Oct; 161(42):5800-3. PubMed ID: 10578695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A case of apparent mineralocorticoid excess caused by type 2 11 beta- hydroxysteroid dehydrogenase deficiency].
    Morineau G; Pascoe L; Marc JM; Caillette A; Krozowski Z; Corvol P; Fiet J
    Arch Mal Coeur Vaiss; 1997 Aug; 90(8):1111-5. PubMed ID: 9404418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human hypertension caused by mutations in the 11 beta-hydroxysteroid dehydrogenase gene: a molecular analysis of apparent mineralocorticoid excess.
    Whorwood CB; Stewart PM
    J Hypertens Suppl; 1996 Dec; 14(5):S19-24. PubMed ID: 9120678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apparent mineralocorticoid excess.
    Funder JW
    Endocrinol Metab Clin North Am; 1995 Sep; 24(3):613-21. PubMed ID: 8575412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apparent mineralocorticoid excess syndrome: report of one family with three affected children.
    Al-Harbi T; Al-Shaikh A
    J Pediatr Endocrinol Metab; 2012; 25(11-12):1083-8. PubMed ID: 23329753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Syndrome of apparent mineralocorticoid excess caused by a deficiency of 11 beta-hydroxysteroid dehydrogenase: clinical and genetic study in a Chilean family followed for 19 years].
    Rodríguez JA
    Rev Med Chil; 2000 Jan; 128(1):17-26. PubMed ID: 10883518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apparent mineralocorticoid excess.
    Benediktsson R; Edwards CR
    J Hum Hypertens; 1994 May; 8(5):371-5. PubMed ID: 8064785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The syndrome of apparent mineralocorticoid excess.
    Cooper M; Stewart PM
    QJM; 1998 Jul; 91(7):453-5. PubMed ID: 9797927
    [No Abstract]   [Full Text] [Related]  

  • 9. [Low-renin hypertension and inherited mineralocorticoid diseases].
    Kastelan D; Giljević Z; Perković Z; Plavsić V; Breskovac L; Aganović I; Korsić M
    Lijec Vjesn; 1999; 121(7-8):245-9. PubMed ID: 10573960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Monogenic hypertension].
    Bähr V; Oelkers W; Diederich S
    Med Klin (Munich); 2003 Apr; 98(4):208-17. PubMed ID: 12715144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [From gene to disease; 'apparent mineralocorticoid excess' syndrome, a syndrome with an apparent excess of mineral corticoids].
    Levtchenko EN; Deinum J; Knoers NV; Hermus AR; Monnens LA; Lenders JW
    Ned Tijdschr Geneeskd; 2007 Mar; 151(12):692-4. PubMed ID: 17447595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A mutation in the cofactor-binding domain of 11beta-hydroxysteroid dehydrogenase type 2 associated with mineralocorticoid hypertension.
    Odermatt A; Dick B; Arnold P; Zaehner T; Plueschke V; Deregibus MN; Repetto H; Frey BM; Frey FJ; Ferrari P
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1247-52. PubMed ID: 11238516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apparent mineralocorticoid excess: report of six new cases and extensive personal experience.
    Morineau G; Sulmont V; Salomon R; Fiquet-Kempf B; Jeunemaître X; Nicod J; Ferrari P
    J Am Soc Nephrol; 2006 Nov; 17(11):3176-84. PubMed ID: 17035606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase.
    Mune T; Rogerson FM; Nikkilä H; Agarwal AK; White PC
    Nat Genet; 1995 Aug; 10(4):394-9. PubMed ID: 7670488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 11 beta-Hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess.
    White PC; Mune T; Rogerson FM; Kayes KM; Agarwal AK
    Pediatr Res; 1997 Jan; 41(1):25-9. PubMed ID: 8979285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apparent mineralocorticoid excess syndromes.
    Shimojo M; Stewart PM
    J Endocrinol Invest; 1995; 18(7):518-32. PubMed ID: 9221270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mineralocorticoid receptors, salt, and hypertension.
    Funder JW; Krozowski Z; Myles K; Sato A; Sheppard KE; Young M
    Recent Prog Horm Res; 1997; 52():247-60; discussion 261-2. PubMed ID: 9238855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio.
    Hood SJ; Taylor KP; Ashby MJ; Brown MJ
    Circulation; 2007 Jul; 116(3):268-75. PubMed ID: 17606839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apparent mineralocorticoid excess type II.
    Mantero F; Tedde R; Opocher G; Dessi Fulgheri P; Arnaldi G; Ulick S
    Steroids; 1994 Feb; 59(2):80-3. PubMed ID: 8191552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypertension and the cortisol-cortisone shuttle.
    Quinkler M; Stewart PM
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2384-92. PubMed ID: 12788832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.